Eli LillyRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Eli Lilly (LLY) reported revenue of $22.97B in Q2 2026, with Cardiometabolic Health its largest revenue segment at 80%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Eli LillyLargest US-listed GLP-1 franchise via Mounjaro (T2D) and Zepbound (obesity). Retatrutide (triple agonist) in Phase 3; orforglipron (oral non-peptide) expected FDA decision Q2 2026. Also major diabetes, oncology, and immunology portfolios.
Eli Lilly (LLY) is a Drug Manufacturers - General company. Largest US-listed GLP-1 franchise via Mounjaro (T2D) and Zepbound (obesity). Retatrutide (triple agonist) in Phase 3; orforglipron (oral non-peptide) expected FDA decision Q2 2026. Also major diabetes, oncology, and immunology portfolios. It was founded in 1876, is headquartered in Indianapolis, IN and employs about 47,000 people.
As of 2026-Q1, Eli Lilly's revenue breaks down across Cardiometabolic Health (80%), Oncology (12%), Immunology (6%), Neuroscience (2%). See the revenue-by-segment chart for the full mix.
Track Eli Lilly's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.
Sterling groups Eli Lilly in the GLP-1 sector, alongside Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), AstraZeneca (AZN) and Viking Therapeutics (VKTX).
If you are researching Eli Lilly, also look at Novo Nordisk (NVO), Pfizer (PFE) and Amgen (AMGN). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.